Immunologic Factor
siltuximab
[ sil-tuk-sih-mab ]
Brand Names:
Sylvant
Effect:
Decreased Immunologic Activity
May Treat:
Castleman Disease
More Information:
Definitions related to siltuximab:
-
A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.NCI ThesaurusU.S. National Cancer Institute, 2021
-
(anti-il-6 chimeric monoclonal antibody) A chimeric (made from human and mouse proteins) monoclonal antibody being studied in the treatment of advanced kidney cancer and other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-IL-6 chimeric monoclonal antibody works by blocking inflammation and tumor growth.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> S
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.